Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

19 MAY 2022

FDA ADVISORY
No. ~~2022-~~1080

TO : **ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

SUBJECT : **Public Health Warning Against the Purchase and Use of the Verified Counterfeit Drug Product "Mefenamic Acid (Ponstan®) 500 mg Tablet"**

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following product:

AUTHENTIC



COUNTERFEIT





Counterfeit – Pfizer logo and the manner of engraving and format of lot number on the blister for collected samples are not aligned with that of the registered product.

Figure 1. Comparison between the Authentic and Counterfeit Mefenamic Acid (Ponstan®) 500 mg Tablet (Lot No. 429-30228A Exp: OCT 2025)

Civic Drive, Filinvest City, Alabang 1781 Muntinlupa, Philippines
Trunk Line +63 2 857 1900 Fax +63 2 807 0751
Website: www.fda.gov.ph Email: info@fda.gov.ph

All healthcare professionals and the general public are hereby warned as to the availability of this counterfeit drug product in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug product only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit product with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug product will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at **info@fda.gov.ph**. To report continuous sale or distribution of unregistered health products, kindly e-mail us via **ereport@fda.gov.ph**, or through the online reporting facility, **eReport**, at **www.fda.gov.ph/ereport**. You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: **https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH** and fill out all the required fields.

Dissemination of the information to all concerned is requested.

DR. OSCAR G. GUTIERREZ, JR.
Officer-in-Charge Director General

DTN: 20220418134517